Professional Marketing briefs: January 2013

Jennifer Cohan
Jennifer Cohan

PR firm GolinHarris is losing managing director Jennifer Cohan to Edelman where she will chair the global consumer practice as of January 2. Cohan currently oversees strategic direction and operations for GolinHarris in addition to acting as an internal consultant for clients Unilever and Olympus. Before GolinHarris, Cohen was deputy manager of Cohen & Wolfe's London operation.

McKesson's Patient Relationship Solutions division has teamed up with Physicians Interactive to bolster the reach of its drug voucher and coupon programs. The agreement will allow PI network members to offer physicians the vouchers and/or coupons along with e-prescriptions. The result: patients can show up at a pharmacy and have the discount built in to the pick-up price.

Shire announced that it is digging deep into rare diseases this year. The company's research will culminate in a 2013 rare diseases impact report that will outline the “health, psycho-social, societal and economic impact of rare disease in patient and medical communities.” The report will be based on research that includes surveys of patients, caregivers, physicians, payers and thought leaders in the US and UK.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.